Foster Karen A.'s Form 4 filing
Biolife Solutions Inc (BLFS) · filed Mar 12, 2024
- Accession no.
- 0001628280-24-010742
- Filed
- Mar 12, 2024
- Trade date
- Mar 8-12, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions. Open-market sales total $91.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Foster Karen A.CIK 0001683151 | Officer (Chief Quality and Operations) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2024 | Common Stock | AGrant or awardAcquired | +20,651 | –F1 | – | 144,591 | Direct | |
| Mar 8, 2024 | Common Stock | AGrant or awardAcquired | +20,445 | –F2 | – | 165,036 | Direct | |
| Mar 11, 2024 | Common Stock | SSaleDisposed | −319 | $17.42 | −$5,556.98 | 164,717 | Direct | |
| Mar 12, 2024 | Common Stock | SSaleDisposed | −5,177 | $16.60 | −$85,938.2 | 159,540 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation.
Referenced by the price of 1 transaction in Table I.
- F2
The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 125% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
Referenced by the price of 1 transaction in Table I.